Glioma is the most common primary intracranial malignancy in the central nervous system. At present, the most important treatment option is surgical resection of the tumor combined with radiotherapy and chemotherapy. The principle of operation is to remove the tumor to the maximal extent on the basis of preserving brain function. However, prominent invasive and infiltrative proliferation of glioma tumor cells into the surrounding normal tissues frequently reduces the efficacy of treatment. This in turn worsens the prognosis, because the tumor cannot be completely removed, which can readily relapse. Chemotherapeutic agents when applied individually have demonstrated limited efficacy for the treatment of glioma. However, multiple different chemotherapeutic agents can be used in combination with other treatment modalities to improve the efficacy while circumventing systemic toxicity and drug resistance. Therefore, it is pivotal to unravel the inhibitory mechanism mediated by the different chemotherapeutic drugs on glioma cells in preclinical studies. The aim of the present review is to provide a summary for understanding the effects of different chemotherapeutic drugs in glioma, in addition to providing a reference for the preclinical research into novel chemotherapeutic agents for future clinical application.
The early clinical symptoms of Takayasu arteritis (TAK) are nonspecific and often lead to misdiagnosis or delay in diagnosis. And by the time morphological changes are observed on the images, the disease is in an advanced stage and irreversible vascular injuries has occurred. Therefore, early correct diagnosis and timely systemic anti-inflammatory treatment can effectively improve the clinical situation. Conventional imaging provides only changes in vascular structure and provides little information on inflammatory activity. Here we report the PET/CT imaging presentation of 18F-deoxyglucose (
18
F-FDG) in a patient with TAK, a 58-year-old patient with known TAK whose disease clustered many non-specific features, and highlight the value of PET/CT in the diagnosis and management of patients with early or atypical clinical presentation of TAK.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.